RAC 2.92% $1.94 race oncology ltd

General Comments / Chat, page-4873

  1. 1,522 Posts.
    lightbulb Created with Sketch. 378
    https://www.biopharmadive.com/news/biotech-10-clinical-trials-watch-2022-first-half/616458/

    Scroll down to Gilead’s breast cancer plans for this year, and the well known $21 billion spent to get the drug’s developer in 2020.

    Given our “platform” now plus heart protection rather than a single drug the value has definitely changed @wombat777
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.